OASMIA PHARMACE/ADR (Nasdaq:OASM) Has Analysts Cautiously Optimistic

OASMIA PHARMACE/ADR (Nasdaq:OASM)

July 27th, 2018

OASMIA PHARMACE/ADR finished Friday’s trading session down 30.93%, a $0.73 decrease to close on $1.63. While the stock did drop today, remember that it is still trading at 104% of its 52 week low of $0.80. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is below the recommended threshold of 1.8%, and calculated to be 1.06.

OASM was outperformed by the rest of the Healthcare sector which went down only 0.53%.

OASMIA PHARMACE/ADR Info

Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The company’s approved products include Paclical/Apealea, a water-soluble formulation of XR17 and paclitaxel to treat cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs. It develops Doxophos, a formulation of XR17 and doxorubicin to treat cancer comprising leukaemia, breast cancer, and lymphoma; Docecal, a formulation of XR17 and docetaxel for the treatment of prostate, lung, and breast cancer; OAS-19, a cancer drug; and KB9520 to treat various types of cancer. The company also develops Doxophos Vet, a formulation to treat lymphoma in dogs. Oasmia Pharmaceutical AB (publ) was founded in 1990 and is based in Uppsala, Sweden.

All amounts in USD unless otherwise indicated

(1) The Altman Z-Score calculation was first published in 1968 by Edward I. Altman, and is used for predicting the probability that a firm will go into bankruptcy within two years. An Altman Z-Score below 1.8 (Remember that OASMIA PHARMACE/ADR’s score is 1.06) is the trigger to be alert for this situation. Some analysts believe this score is less relevant for some companies, in particular companies operating to accumulate users that may run at huge losses to scale up.

OASM daily update
OASM daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.